Search for a trial

GLOBAL STUDY TO ASSESS THE ADDITION OF BEVACIZUMAB TO CARBOPLATIN AND PACLITAXEL AS FRONT-LINE TREATMENT OF EPITHELIAL OVARIAN CANCER, FALLOPIAN TUBE CARCINOMA OR PRIMARY PERITONEAL CARCINOMA

Zie pagina 39-40 van het protocol MO22923 versie 2, 26 Mei 2011

Regional study into the performance and cost-effectiveness of simple ultrasound-based rules compared to the currently used Risk of Malignancy Index (RMI) in the diagnosis of ovarian cancer.

This study is performed to compare the diagnostic performance and cost-effectiveness of different methods in the preoperative characterization of ovarian masses: RMI compared toa) simple ultrasound-based rules as a first step test and subjective…

Pilot study of the lavage of the uterine cavity for the diagnosis of serous tubal intraepithelial carcinoma

Detect exfoliated cells from STICs in lavage fluid from the uterine cavity and proximal fallopian tubes

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of MORAb-003 (farletuzumab) in Combination with Paclitaxel Therapy in Subjects with Platinum-Resistant or Refractory Relapsed Ovarian Cancer

To compare the effect of paclitaxel plus MORAb-003 to paclitaxel plus placebo on progression free survival (PFS) as determined by RECIST in subjects who are in a first platinum-resistant or refractory relapse of ovarian cancer.

Molecular mechanisms behind presumed reduced ovarian reserve and embryo competence in BRCA1/2-mutation carriers in IVF/PGD

Analyze processes related to DNA-damage in oocyte development and early-developmental stage embryos from BRCA1/2-mutation carriers compared to controls, using immunohistochemistry and RNA-Seq technology.

A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients who have achieved a Complete Clinical Response after Standard Platinum/Taxane Containing Chemotherapy

The objective of this phase IIb is to compare the efficacy and safety of sorafenib to placebo of patients with ovarian epithelial or primary peritoneal cancers stage IIIb and IV who have achieved a complete clinical response after standard platinum/…

p53 synthetic long peptides vaccine with cyclophosphamide for ovarian cancer, a phase II trial.

Primary objectives:- To improve the clinical effectiveness of the p53 synthetic long peptides vaccine by pre-administration of cyclophosphamide.- To evaluate the immunogenicity of a p53 synthetic long peptide vaccine when preceded by administration…

The role of inactive follicle stimulating hormone in ovarian dysfunction in galactosemia.

1) To assess whether galactosemia women with ovarian failure are able to produce estradiol after exogenous (normally bioactive) FSH and LH gift 2) To characterize FSH glycan structures

Preferential study of women with adnexal masses considering frozen section diagnosis.

The objective of the study is to examine the opinion of women about the accuray of frozen section diagnosis. A important question is how women feel about a second operation in case of a false negative testresult.

Integrated 18F-FDG PET/CT in the staging of patients with suspected primary ovarian cancer.

The aim of the study is to prospectively evaluate the accuracy of integrated whole body positron emission tomography/computed tomography (PET/CT) in staging patients with primary ovarian cancer, with use of histological findings as the reference…

A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers

To estimate the treatment effect and safety of AMG 386 in combination with paclitaxel + carboplatin in subjects with FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers.

Subcellular components and multi-drug resistance in epithelial ovarian carcinoma

The purpose of this study is to investigate the characteristics of different sub cellular constituents in different body fluids of patients with advanced EOC with different histotypes. Besides obtaining more clarity about the role of these…

[18F]fluoro-PEG-folate PET/CT imaging in patients with epithelial ovarian cancer

Primary objective:1. To evaluate the safety and tolerability of the [18F]fluoro-PEG-folate PET tracer2. To determine the pharmacokinetics (protein binding, biodistribution, clearance rate) of the [18F]fluoro-PEG-folate PET tracerSecondary objectives…

A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR 042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER

This study has been transitioned to CTIS with ID 2024-510605-28-00 check the CTIS register for the current data. Primary Objective• To compare the progression free survival (PFS) of programmed death-ligand 1 (PD-L1) positive patients with Stage III…

A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression

This study has been transitioned to CTIS with ID 2023-505455-44-00 check the CTIS register for the current data. Part 1 (phase 1b)Primary:• To observe the safety and tolerability of bemarituzumabSecondary:• To evaluate preliminary antitumor activity…

The Netherlands Chlamydia Cohort Study: assessing the risk of late complications after Chlamydia trachomatis infection in women

The aim of the NEtherlands Chlamydia Cohort STudy (NECCST) is to assess the risk of developing complications and the time to pregnancy in women with and without a known previous Ct infection. Furthermore, this study aims at determining host genetic…

Selecting Ovarian Cancer patients for PARP Inhibitor (SOPI) study

The main objective of the SOPI study is to select the HRD test that best predicts longest PFS on PARP-i in non-BRCA1/2 EOC patients, in order to adequately select patients that will benefit from a PARP-i. Secondary objectives are: to evaluate the 1-…

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96 / ENGOT-ov65)

This study has been transitioned to CTIS with ID 2023-506177-35-00 check the CTIS register for the current data. Objective: To compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab,…

Clinical outcome of routine treatment of patients with Pelvic Inflammatory Disease and/or Tubo Ovarial Abcess in the presence or absence of Mycoplasma genitalium (MG)

The primary aim of the present study is to investigate whether current standard treatment for PID is clinically effective in patients in whom Mycoplasma genitalium (MG) is present. A secondary aim of the study is to asses whether this treatment is…

OPINION - A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed non-Germline BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy

This research study is designed to check whether olaparib is also effective in treating ovarian cancer which does not have a germline deleterious BRCA mutation, and whether olaparib causes any side effects.A tablet formulation of olaparib is being…